These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 17161610)

  • 1. Intermittent chemotherapy for metastatic hormone refractory prostate cancer.
    Lin AM; Ryan CJ; Small EJ
    Crit Rev Oncol Hematol; 2007 Mar; 61(3):243-54. PubMed ID: 17161610
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Achieving treatment goals for hormone-refractory prostate cancer with chemotherapy.
    Berry W; Eisenberger M
    Oncologist; 2005; 10 Suppl 3():30-9. PubMed ID: 16368869
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New standards in the chemotherapy of metastatic hormone-refractory prostate cancer.
    Sava T; Basso U; Porcaro A; Cetto GL
    Expert Rev Anticancer Ther; 2005 Feb; 5(1):53-62. PubMed ID: 15757438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group.
    Calais da Silva FE; Bono AV; Whelan P; Brausi M; Marques Queimadelos A; Martin JA; Kirkali Z; Calais da Silva FM; Robertson C
    Eur Urol; 2009 Jun; 55(6):1269-77. PubMed ID: 19249153
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is there a role for platinum chemotherapy in the treatment of patients with hormone-refractory prostate cancer?
    Oh WK; Tay MH; Huang J
    Cancer; 2007 Feb; 109(3):477-86. PubMed ID: 17186531
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemotherapy for the treatment of hormone-refractory prostate cancer.
    Chowdhury S; Burbridge S; Harper PG
    Int J Clin Pract; 2007 Dec; 61(12):2064-70. PubMed ID: 17956560
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of hormone refractory prostate cancer.
    Lin AM; Small EJ
    Curr Opin Support Palliat Care; 2007 Oct; 1(3):187-91. PubMed ID: 18685361
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hormone refractory prostate cancer (HRPC): present and future approaches of therapy.
    Di Lorenzo G; De Placido S
    Int J Immunopathol Pharmacol; 2006; 19(1):11-34. PubMed ID: 16569343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. American Society of Clinical Oncology endorsement of the Cancer Care Ontario Practice Guideline on nonhormonal therapy for men with metastatic hormone-refractory (castration-resistant) prostate cancer.
    Basch EM; Somerfield MR; Beer TM; Carducci MA; Higano CS; Hussain MH; Scher HI;
    J Clin Oncol; 2007 Nov; 25(33):5313-8. PubMed ID: 17925542
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Second-line chemotherapy for advanced hormone-refractory prostate cancer.
    Garmey EG; Sartor O; Halabi S; Vogelzang NJ
    Clin Adv Hematol Oncol; 2008 Feb; 6(2):118-22, 127-32. PubMed ID: 18347563
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The study landscape for prostate cancer].
    Miller K
    Urologe A; 2005 Dec; 44(12):1431-4. PubMed ID: 16292461
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of doxorubicin and epirubicin in the treatment of patients with metastatic hormone-refractory prostate cancer.
    Petrioli R; Fiaschi AI; Francini E; Pascucci A; Francini G
    Cancer Treat Rev; 2008 Dec; 34(8):710-8. PubMed ID: 18620815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anticancer effect of combination therapy of VP16 and fosfesterol in hormone-refractory prostate cancer.
    Azuma H; Sakamoto T; Kiyama S; Ubai T; Kotake Y; Inamoto T; Takahara K; Nishimura Y; Segawa N; Katsuoka Y
    Am J Clin Oncol; 2008 Apr; 31(2):188-94. PubMed ID: 18391605
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intermittent hormone therapy and its place in the contemporary endocrine treatment of prostate cancer.
    Shaw G; Oliver RT
    Surg Oncol; 2009 Sep; 18(3):275-82. PubMed ID: 19269165
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diethylstilbestrol and docetaxel: a Phase II study of tubulin active agents in patients with metastatic, androgen-independent prostate cancer.
    Montgomery RB; Nelson PS; Lin D; Ryan CW; Garzotto M; Beer TM
    Cancer; 2007 Sep; 110(5):996-1002. PubMed ID: 17639587
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of the spectrum of hormone refractory prostate cancer.
    Clarke NW
    Eur Urol; 2006 Sep; 50(3):428-38; discussion 438-9. PubMed ID: 16797118
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Survival after cytotoxic chemotherapy in patients with advanced hormone-resistant prostate cancer: a phase II study.
    Stathopoulos GP; Koutantos J; Vaslamatzis MM; Athanasiadis A; Papadopoulos G; Labrodimou G; Stathopoulos J; Rigatos S
    Oncol Rep; 2009 Aug; 22(2):345-8. PubMed ID: 19578775
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The case for early chemotherapy for the treatment of metastatic disease.
    Lucas A; Petrylak DP
    J Urol; 2006 Dec; 176(6 Pt 2):S72-5. PubMed ID: 17084173
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Current place of chemotherapy in the treatment of hormone-refractory metastatic prostate cancer].
    Breton X; Lechevallier E; Coulange C
    Prog Urol; 2005 Jun; 15(3):398-404. PubMed ID: 16097142
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of systemic cytotoxic therapy for prostate cancer.
    Chang SS; Kibel AS
    BJU Int; 2009 Jan; 103(1):8-17. PubMed ID: 19040524
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.